Oregonin inhibits inflammation and protects against barrier disruption in intestinal epithelial cells.
CONCLUSION: The findings of this study suggest that oregonin is a potential candidate for treatment of IBD by preventing mucosal inflammation and barrier disruption.
PMID: 29655054 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Chi JH, Seo GS, Lee SH Tags: Int Immunopharmacol Source Type: research
More News: Inflammatory Bowel Disease | Study